Molecular and neurochemical mechanisms in PD pathogenesis

Neurotoxicity Research

Volumn 16, Issue 3, 2009, Pages 271-279

  Paris, Irmgard ^a   Lozano, Jorge ^a   Perez Pastene, Carolina ^a   Muñoz, Patricia ^a   Segura Aguilar, Juan ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

6 Hydroxydopamine; Alpha synuclein; Aminochrome; Copper; Dopamine; Iron; MPTP; Neuroprotection; Parkinson's disease; Reserpine; Rotenone; VMAT 2

Indexed keywords

ALPHA SYNUCLEIN; AMINOCHROME; DOPAMINE; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ARTICLE; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; ENZYME LOCALIZATION; HUMAN; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION;

ANIMALS; CELL DEATH; DOPAMINE; FMN REDUCTASE; HUMANS; INDOLEQUINONES; INTERMEDIATE FILAMENT PROTEINS; MODELS, BIOLOGICAL; NERVE DEGENERATION; NEUROCHEMISTRY; NEUROTOXINS; PARKINSON DISEASE;

EID: 70349897077     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12640-009-9059-4     Document Type: Article

References (96)

1. Aguilar Hernandez R, Sanchez De Las Matas MJ, Arriagada C, Barcia C, Caviedes P, Herrero MT, Segura-Aguilar J (2003) MPP(+)-induced degeneration is potentiated by dicoumarol in cultures of the RCSN-3 dopaminergic cell line. Implications of neuromelanin in oxidative metabolism of dopamine neurotoxicity. Neurotoxicity Res 5:407-410
2. Alerte TN, Akinfolarin AA, Friedrich EE, Mader SA, Hong CS, Perez RG (2008) Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: Lessons from viral transduction of knockout mice. Neurosci Lett 435:24-29
3. Alvarez-Fischer D, Henze C, Strenzke C, Westrich J, Ferger B, Höglinger GU, Oertel WH, Hartmann A (2008) Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp Neurol 210:182-193
4. Arriagada A, Paris I, Sanchez de las Matas MJ, Martinez-Alvarado P, Cardenas S, Castañeda P, Graumann R, Perez-Pastene C, Olea-Azar C, Couve E, Herrero MT, Caviedes P, Segura-Aguilar J (2004) On the neurotoxicity of leuko aminochrome o-semiquinone radical derived of dopamine oxidation: Mitochondria damage, necrosis and hydroxyl radical formation. Neurobiol Dis 16:468-477
5. Baez S, Linderson Y, Segura-Aguilar J (1995) Superoxide dismutase and catalase enhance autoxidation during one-electron reduction of aminochrome by NADPH-cytochrome P-450 reductase. Biochem Mol Med 54:12-18
6. Ben Gedalya T, Loeb V, Israeli E, Altschuler Y, Selkoe DJ, Sharon R (2009) Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic 10:218-234
7. Berg D, Niwar M, Maass S, Zimprich A, Moller JC, Wuellner U, Schmitz-Hubsch T, Klein C, Tan EK, Schols L, Marsh L, Dawson TM, Janetzky B, Müller T, Woitalla D, Kostic V, Pramstaller PP, Oertel WH, Bauer P, Krueger R, Gasser T, Riess O (2005) Alpha-synuclein and Parkinson's disease: Implications from the screening of more than 1,900 patients. Mov Disord 20:1191-1194
8. Buchman VL, Ninkina N (2008a) Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies - is the juice worth the squeeze? Neurotox Res 14:329-341
9. Buchman VL, Ninkina N (2008b) Mouse models for studying function of synuclein family members in the normal and degenerating brain. Neurotox Res 13:121
10. Cardenas S, Paris I, Fuentes-Bravo P, Graumann R, Riveros A, lozano J, Calegaro M, Caviedes P, Segura-Aguilar J (2008a) DT-diaphorase protection in catecholaminergic cell line against aminochrome neurotoxic effects. Neurotox Res 13:120
11. Cardenas SP, Perez-Pastene C, Couve E, Segura-Aguilar J (2008b) The DT-diaphorase prevents the aggregation of a-synuclein induced by aminochrome. Neurotoxicity Res 13:136
12. Chen Q, Thorpe J, Keller JN (2005) Alpha-synuclein alters proteasome function, protein synthesis, and stationary phase viability. J Biol Chem 280:30009-30017
13. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97:571-576
14. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294:1346-1349
15. Crews L, Mizuno H, Desplats P, Rockenstein E, Adame A, Patrick C, Winner B, Winkler J, Masliah E (2008) Alpha-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice. J Neurosci 28:4250-4260
16. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305:1292-1295
17. Díaz-Véliz G, Mora S, Dossi MT, Gómez P, Arriagada C, Montiel J, Aboitiz F, Segura-Aguilar J (2002) Behavioral effects of aminochrome and dopachrome injected in the rat substantia nigra. Pharmacol Biochem Behav 73:843-850
18. Diaz-Veliz G, Mora S, Lungenstrass H, Segura-Aguilar J (2004a) Inhibition of DT-diaphorase potentiates the in vivo neurotoxic effect of intranigral injection of salsolinol in rats. Neurotox Res 5:629-633
19. Diaz-Veliz G, Mora S, Gomez P, Dossi MT, Montiel J, Arriagada C, Aboitiz F, Segura-Aguilar J (2004b) Behavioral effects of manganese injected in the rat substantia nigra are potentiated by dicumarol, a DT-diaphorase inhibitor. Pharmacol Biochem Behav 77:245-251
20. Diaz-Veliz G, Paris I, Mora S, Raisman-Vozari R, Segura-Aguilar J (2008) Copper neurotoxicity in rat substantia nigra and striatum is dependent on DT-diaphorase inhibition. Chem Res Toxicol 21:1180-1185
21. Duka T, Sidhu A (2006) The neurotoxin, MPP+, induces hyperphosphorylation of Tau, in the presence of alpha-synuclein, in SH-SY5Y neuroblastoma cells. Neurotox Res 10:1-10
22. Duka T, Rusnak M, Drolet RE, Duka V, Wersinger C, Goudreau JL, Sidhu A (2006) Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of Parkinsonism. FASEB J 20:2302-2312
23. Fernández CO (2008) Synucleinnopathies: Structural features and molecular interactions. Neurotox Res 13:120
24. Follmer C, Romão L, Einsiedler CM, Porto TC, Lara FA, Moncores M, Weissmüller G, Lashuel HA, Lansbury P, Neto VM, Silva JL, Foguel D (2007) Dopamine affects the stability, hydration, and packing of protofibrils and fibrils of the wild type and variants of alpha-synuclein. Biochemistry 46:472-482
25. Foppoli C, Coccia R, Cini C, Rosei MA (1997) Catecholamines oxidation by xanthine oxidase. Biochim Biophys Acta 1334:200-206
26. Fuentes P, Paris I, Nassif M, Caviedes P, Segura-Aguilar J (2007) Inhibition of VMAT-2 and DT-Diaphorase induce cell death in a substantia nigra-derived cell line-an experimental cell model for dopamine toxicity studies. Chem Res Toxicol 20:776-783
27. Galzigna L, De Iuliis A, Zanatta L (2000) Enzymatic dopamine peroxidation in substantia nigra of human brain. Clin Chim Acta 300:131-138
28. Gauthier MA, Eibl JK, Crispo JA, Ross GM (2008) Covalent arylation of metallothionein by oxidized dopamine products: A possible mechanism for zinc-mediated enhancement of dopaminergic neuron survival. Neurotox Res 14:317-328
29. Glaser CB, Yamin G, Uversky VN, Fink AL (2005) Methionine oxidation, alpha-synuclein and Parkinson's disease. Biochim Biophys Acta 1703:157-169
30. Hastings TG (1995) Enzymatic oxidation of dopamine: The role of prostaglandin H synthase. J Neurochem 64:919-924
31. Herrera-Marschitz M, Bustamante D, Morales P, Goiny M (2007) Exploring neurocircuitries of the basal ganglia by intracerebral administration of selective neurotoxins. Neurotox Res 11:169-182
32. Hokenson MJ, Uversky VN, Goers J, Yamin G, Munishkina LA, Fink AL (2004) Role of individual methionines in the fibrillation of methionine-oxidized alpha-synuclein. Biochemistry 43:4621-4633
33. Ikeda M, Kawarabayashi T, Harigaya Y, Sasaki A, Yamada S, Matsubara E, Murakami T, Tanaka Y, Kurata T, Wuhua X, Ueda K, Kuribara H, Ikarashi Y, Nakazato Y, Okamoto K, Abe K, Shoji M (2009) Motor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T transgenic mice with alpha-synuclein pathology. Brain Res 1250:232-241
34. Jenner P (2005) Mechanisms of cell death in Parkinson's disease. Neurotox Res 8:310
35. Kontopoulos E, Parvin JD, Feany MB (2006) Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 15:3012-3023
36. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Gen 18:106-108
37. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T Jr, Lansbury PT (2002) Alpha-synuclein, especially the Parkinson's disease-associated mutants forms pore-like annular and tubular protofibrils. J Mol Biol 322:1089-1102
38. LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat Med 11:1159-1161
39. Li HT, Lin DH, Luo XY, Zhang F, Ji LN, Du HN, Song GQ, Hu J, Zhou JW, Hu HY (2005) Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration. FEBS J 272:3661-3672
40. Manning-Bog AB, Langston JW (2007) Model fusion, the next phase in developing animal models for Parkinson's disease. Neurotox Res 11:219-240
41. Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, Hodara R, Fredenburg R, Wu DC, Follenzi A, Dauer W, Przedborski S, Ischiropoulos H, Lansbury PT, Sulzer D, Cuervo AM (2008) Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 118:777-788
42. Marxreiter F, Nuber S, Kandasamy M, Klucken J, Aigner R, Burgmayer R, Couillard-Despres S, Riess O, Winkler J, Winner B (2009) Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of alpha-synuclein. Eur J NeuroSci 29:879-890
43. Mazzulli JR, Mishizen AJ, Giasson BI, Lynch DR, Thomas SA, Nakashima A, Nagatsu T, Ota A, Ischiropoulos H (2006) Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J Neurosci 26:10068-10078
44. Mazzulli JR, Armakola M, Dumoulin M, Parastatidis I, Ischiropoulos H (2007) Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C terminal sequence. J Biol Chem 282:31621-31630
45. Munishkina LA, Fink AL, Uversky VN (2008) Concerted action of metals and macromolecular crowding on the fibrillation of alpha-synuclein. Protein Pept Lett 15:1079-1085
46. Norris EH, Giasson BI, Hodara R, Xu S, Trojanowski JQ, Ischiropoulos H, Lee VM (2005) Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J Biol Chem 280:21212-21219
47. Nuber S, Petrasch-Parwez E, Winner B, Winkler J, von Hörsten S, Schmidt T, Boy J, Kuhn M, Nguyen HP, Teismann P, Schulz JB, Neumann M, Pichler BJ, Reischl G, Holzmann C, Schmitt I, Bornemann A, Kuhn W, Zimmermann F, Servadio A, Riess O (2008) Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J Neurosci 28:2471-2484
48. Paleologou KE, Schmid AW, Rospigliosi CC, Kim HY, Lamberto GR, Fredenburg RA Jr, Lansbury PT, Fernandez CO, Eliezer D, Zweckstetter M, Lashuel HA (2008) Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem 283:16895-16905
49. Paris I, Dagnino-Subiabre A, Marcelain K, Bennett LB, Caviedes P, Caviedes R, Olea-Azar C, Segura-Aguilar J (2001) Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line. J Neurochem 77:519-529
50. Paris I, Martinez-Alvarad P, Cardenas S, Perez-Pastene C, Graumann R, Fuentes P, Olea-Azar C, Caviedes P P, Segura-Aguilar J (2005a) Dopamine-dependent iron toxicity in cells derived from rat hypothalamus. Chem Res Toxicol 18:415-419
51. Paris I, Martinez-Alvarado P, Perez-Pastene C, Vieira MN, Olea-Azar C, Raisman-Vozari R, Cardenas S, Graumann R, Caviedes P, Segura-Aguilar J (2005b) Monoamine transporter inhibitors and norepinephrine reduce dopamine-dependent iron toxicity in cells derived from the substantia nigra. J Neurochem 92:1021-1032
52. Paris I, Cardenas S, Perez-Pastene C, Lozano J, Graumann R, Riveros A, Caviedes P, Segura-Aguilar J (2007) Aminochrome as preclinical model to study degeneration of dopaminergic neurons in Parkinson's Disease. Neurotox Res 12:125-134
53. Paris I, Lozan J, Cardenas, Perez-Pastene C, Saud K, Fuentes P, Caviedes P, Dagnino-Subiabre A, Raisman-Vozari R, Shimahara T, Kostrzewa JP, Chi D, Kostrzewa RM, P Caviedes R, SeguraAguilar J (2008) The catecholaminergic RCSN-3 cell line: A model to study dopamine metabolism. Neurotox. Res. 13, 221-230
54. Park JY, Lansbury PT Jr (2003) Beta-synuclein inhibits formation of alpha-synuclein protofibrils: A possible therapeutic strategy against Parkinson's disease. Biochemistry 42:3696-3700
55. Peng X-M, Tehranian R, Dietrich P, Stefanis L, Perez RG (2005) Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J Cell Sci 118:3523-3530
56. Perez RG, Waymire J, Lin E, Liu JJ, Guo F, Zigmond MJ (2002) A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 22:3090-3099
57. Plaas M, Karis A, Innos J, Rebane E, Baekelandt V, Vaarmann A, Luuk H, Vasar E, Koks S (2008) Alpha-synuclein A30P point-mutation generates age-dependent nigrostriatal deficiency in mice. J Physiol Pharmacol 59:205-216
58. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047
59. Riveros A, Cuchillo I, Hanger D, Segura-Aguilar J, Stephenson J (2008) Studies on the effect of the aminochrome treatment in the axonal transport of alpha-synuclein. Neurotox Res 13:147
60. Schell H, Hasegawa T, Neumann M, Kahle PJ (2009) Nuclear and Neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Neuroscience 160:796-804
61. Schultzberg M, Segura-Aguilar J, Lind C (1988) Distribution of DT-diaphorase in the rat brain: Biochemical and immunohistochemical studies. Neuroscience 27:763-766
62. Segura-Aguilar J (1989) Properties, isoforms, localization in the rat brain and possible role in dopamine metabolism. Academitryck AB, Stockholm, ISBN -91-7146-783-1
63. Segura-Aguilar J (1996) Peroxidase activity of liver microsomal vitamin D 25 hydroxylase catalyzes 25-hydroxylation of vitamin D3 and oxidation of dopamine to aminochrome. Biochem Mol Med 58:122-129
64. Segura-Aguilar J, Kostrzewa RM (2006) Neurotoxins and neurotoxicity mechanisms. An overview. Neurotox Res 10:263-287
65. Segura-Aguilar J, Lind C (1989) On the mechanism of Mn3+ induced neurotoxicity of dopamine: Prevention of quinone derived oxygen toxicity by DT-diaphorase and superoxide dismutase. Chem Biol Interact 72:309-324
66. Segura-Aguilar J, Metodiewa D, Welch C (1998) Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim Biophys Acta 1381:1-6
67. Segura-Aguilar J, Metodiewa D, Baez S (2001) The possible role of one electron reduction of aminochrome in the neurodegenerative processes of the dopaminergic systems. Neurotox Res 3:157-166
68. Segura-Aguilar J, Diaz-Veliz G, Mora S, Herrera-Marschitz M (2002) Inhibition of DTdiaphorase is a requirement for Mn3+ to produce a 6-OH-dopamine like rotational behaviour. Neurotoxicity Res 4:127-131
69. Segura-Aguilar J, Cardenas S, Riveros A, Fuentes-Bravo P, Lozano J, Graumann R, Paris I, Nassif M, Caviedes P (2006) DT-diaphorase prevents the formation of alpha-synuclein adducts with aminochrome Soc Neurosci Abstr 824:17
70. Simola N, Morelli M, Carta AR (2007) The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res 11:151-167
71. Smythies J, De Iuliis A, Zanatta L, Galzigna J (2002) The biochemical basis of Parkinson's disease: ThA role of catecholamine o-quinones: a review-discussion. Neurotox Res 4:77-81
72. Sotiriou E, Vassilatis DK, Vila M, Stefanis L (2009) Selective noradrenergic vulnerability in alpha-synuclein transgenic mice Neurobiol Aging [Epub ahead of print]
73. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha synuclein in Lewy bodies. Nature 388:839-840
74. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95:6469-6473
75. Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ (2008) Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging 29:1690-1701
76. Sulzer D, Talloczy Z, Mosharov EM, Martinez-Vicente M, Cuervo AM (2008) Alpha synuclein and autophagy as an early step in Parkinson's disease. Neurotox Res 13:120
77. Terland O, Flatmark T, Tangeras A, Gronberg M (1997) Dopamine oxidation generates an oxidative stress mediated by dopamine semiquinone and unrelated to reactive oxygen species. J Mol Cell Cardiol 29:1731-1738
78. Thompson CM, Capdevila JH, Strobel HW (2000) Recombinant cytochrome P450 2D18 metabolism of dopamine and arachidonic acid. J Pharmacol Exp Ther 294:1120-1130
79. Uversky VN (2008) Alpha-synuclein misfolding and neurodegenerative diseases. Curr Protein Pept Sci 9:507-540
80. Volles MJ, Lansbury PT Jr (2003) Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42:7871-7878
81. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC Jr, Lansbury PT (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: Implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40:7812-7819
82. Wakamatsu M, Ishii A, Ukai Y, Sakagami J, Iwata S, Ono M, Matsumoto K, Nakamura A, Tada N, Kobayashi K, Iwatsubo T, Yoshimoto M (2007) Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. J Neurosci Res 85:1819-1825
83. Whitehead RE, Ferrer JV, Javitch JA, Justice JB (2001) Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J Neurochem 76:1242-1251
84. Williams A (1984) MPTP Parkinsonism. Br Med J 289:1401-1402
85. Winner B, Rockenstein E, Lie DC, Aigner R, Mante M, Bogdahn U, Couillard-Despres S, Masliah E, Winkler J (2008) Mutant alpha-synuclein exacerbates age-related decrease of neurogenesis. Neurobiol Aging 29:913-925
86. Wislet-Gendebien S, Visanji NP, Whitehead SN, Marsilio D, Hou W, Figeys D, Fraser PE, Bennett SA, Tandon A (2008) Differential regulation of wild-type and mutant alpha-synuclein binding to synaptic membranes by cytosolic factors. BMC Neurosci 9:92
87. Xu Y, Stokes AH, Roskoski R Jr, Vrana KE (1998) Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J Neurosci Res 54:691-697
88. Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8:600-606
89. Yamin G, Glaser CB, Uversky VN, Fink AL (2003a) Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein. J Biol Chem 278:27630-27635
90. Yamin G, Uversky VN, Fink AL (2003b) Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett 542:147-152
91. Yu WH, Matsuoka Y, Sziráki I, Hashim A, Lafrancois J, Sershen H, Duff KE (2008) Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein. Neurochem Res 33:902-911
92. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Muñoz DG, de Yebenes JG (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164-173
93. Zecca L, Fariello R, Riederer P, Sulzer D, Gatti A, Tampellini D (2002) The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett 510:216-220
94. Zhao DL, Zou LB, Zhou LF, Zhu P, Zhu HB (2007) A cell-based model of alpha-synucleinopathy for screening compounds with therapeutic potential of Parkinson's disease. Acta Pharmacol Sin 28:616-626
95. Zhou W, Hurlbert MS, Schaack J, Prasad KN, Freed CR (2000) Overexpression of human alphasynuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon derived cells. Brain Res 866:33-43
96. Zhu M, Li J, Fink AL (2003) The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J Biol Chem 278:40186-40197